Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
“We are very excited to have Bill and Joe, two industry executives with a tremendous breadth of experience and a strong track record of accomplishments, join our Board of Directors. We believe that Aileron will benefit greatly from their scope and depth of operational insight and experience,” said Dr.
Mr. McKee commented, “I am excited about the prospects for ALRN-6924, and the broad applicability of Aileron’s stabilized cell-permeating peptide platform. I look forward to working with the management team and the Board to advance this promising lead program and to help Aileron build and strengthen its operational capabilities.”
“I believe Aileron’s stabilized cell-permeating peptide platform technology is very promising. Aileron’s current clinical focus, combining ALRN-6924 with Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified tumors, along with its plans to commence a myelopreservation trial with ALRN-6924 in September for cancer patients receiving chemotherapy, both represent exciting opportunities. Furthermore, I believe this platform is capable of producing additional novel drug candidates that address previously undruggable targets,” said Mr.
Mr. McKee is a seasoned pharmaceutical industry executive and consultant. Currently, Mr. McKee serves as the Chief Executive Officer of
ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its interactions with both its endogenous inhibitors, MDMX and MDM2. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov.
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in drug candidates like ALRN-6924. Our current focus is to improve the standard of care for patients with cancer by developing safe and effective therapies that leverage our proprietary peptide platform. For more information, visit www.aileronrx.com, and for more information about our clinical trials please visit www.clinicaltrials.gov.
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the
LifeSci Advisors, LLC.
Source: Aileron Therapeutics, Inc.